NeurologyLive® Friday 5 — December 2, 2022

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Mind Moments® Episode 78: A Virtual Reality Platform for Parkison Disease

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD, on the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping platform works towards that understanding. [LISTEN TIME: 27 minutes]

Mind Moments® Episode 78: A Virtual Reality Platform for Parkison Disease

2: The Expectations for the 2023 MDA Conference: Donald S. Wood, PhD; Sharon Hesterlee, PhD

The president and CEO, as well as the executive vice president and chief research officer, of MDA, together offered an in-depth overview of what to expect from the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas. [WATCH TIME: 12 minutes]

The Expectations for the 2023 MDA Conference: Donald S. Wood, PhD; Sharon Hesterlee, PhD

3: NeuroVoices: Carrie Hersh, DO, MSc, on Applying 2-Stage Models to Improve Disease-Modifying Therapy Selection in MS

In the latest edition of our in-depth Q&A series, the associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on the incorporation of real-world methods to optimize treatment selection for multiple sclerosis.

NeuroVoices: Carrie Hersh, DO, MSc, on Applying 2-Stage Models to Improve Disease-Modifying Therapy Selection in MS

4: Coverage of the Clinical Trials on Alzheimer Disease Congress

The Clinical Trials on Alzheimer's Disease Conference (CTAD) includes a focus on Alzheimer disease (AD) therapeutic trials, featuring leaders in AD research from industry and academia with an aim of forming partnerships to progress the development of effective treatments to fight the disease.

Coverage of the Clinical Trials on Alzheimer Disease Congress

5: Peers & Perspectives: Sleep and Wakefulness Pathways

In episode 7 of this NeurologyLive® Peers & Perspectives series, Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, Debra Davis, CRNP provide an overview of pathways and neurotransmitters involved in sleep and wake cycles.

Peers & Perspectives: Sleep and Wakefulness Pathways

—————————————————

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.